INOVIO wins $80.4 million judgment against VGXI and GeneOne
+1 new source since this summary was written
INOVIO Pharmaceuticals secured a court judgment of $80,416,101 in Pennsylvania, comprising $61,750,789 in compensatory damages and $18,665,312 in fees and costs, after VGXI and GeneOne breached a supply agreement. The company filed the case on June 3 2020 and plans to pursue collection, but warns that the defendants’ financial condition may limit recoveries. Cooley LLP and FBT Gibbons represented INOVIO in the trial.
Why it matters
The judgment adds a potential $80.4 million asset to INOVIO’s balance sheet, but actual cash recovery depends on the defendants’ ability to pay, creating uncertainty for investors. The company’s forward‑looking statements note that collection may be reduced, reversed, or otherwise modified.
Key facts
- 1The court awarded INOVIO $61,750,789 in compensatory damages. prnewswire.com
- 2The court awarded INOVIO $18,665,312 in fees and costs. prnewswire.com
- 3The total judgment amount was $80,416,101. prnewswire.com
- 4INOVIO filed the case on June 3 2020 alleging breach of a Supply Agreement. stocktitan.net
- 5Defendants’ financial condition may impair INOVIO’s ability to collect the judgment. stocktitan.net
- 6Cooley LLP and FBT Gibbons served as trial counsel for INOVIO. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.